CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.

We demonstrate a clear trend towards increased CD70 expression in rGBM compared with pGBM in our CSC-enriched cell populations; though not statistically significant, bulk tumor data also demonstrates a trend toward increased CD70 expression in recurrent vs primary samples 69 ( figure 1D , online supplemental figure 1B ).

also in 19,460 other papers